Geode Capital Management’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
Other funds holding KROS
Geode Capital Management's KROS Position: Q3 2026 in Review
Geode Capital Management reduced its Keros Therapeutics (KROS) stake by 2.9% in Q3 2026, selling an estimated $161K and leaving 496,165 shares worth $5.66M. The position accounts for ﹤0.01% of the portfolio, ranked #2789.
Geode Capital Management first reported a position in KROS in Q2 2020 and has held it in 26 quarters since. The position peaked at $42.1M in Q3 2024. 135 funds tracked by Wall St. Rank hold KROS as of Q3 2026.
- Geode Capital Management held 496,165 shares of Keros Therapeutics worth $5.66M as of Q3 2026.
- Geode Capital Management sold 14,676 Keros Therapeutics shares in Q3 2026, an estimated $161K.
- Keros Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #2789 holding.
- Geode Capital Management first reported a position in Keros Therapeutics in Q2 2020 and has held it in 26 quarters since.
- Geode Capital Management's Keros Therapeutics position peaked at $42.1M in Q3 2024.
- 135 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2026.
Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.